2023 ISMRM & ISMRT Annual Meeting & Exhibition

2023 ISMRM Annual Meeting
Call for Late-Breaking Abstracts

Deadline:

We have planned some extra space for a late-breaking oral session on neuroinflammation, which is related to our second Clinical Focus Meeting: Imaging the Fire in the Brain.

Did you have work that didn’t quite make it to the November abstract deadline? Does your research work on neuroinflammatory processes have the potential to translate into clinical practice? Does your research work on neuroinflammation relate to novel MRI techniques that you would like to present to the ISMRM community? This is your chance.

Abstracts will need to be uploaded to the abstract submission site following the same format and guidelines as abstracts submitted in November. Please note that late-breaking abstracts must be NEW submissions and not work previously accepted by the Society (including to the 2023 meeting) nor submitted elsewhere.

Start preparing your abstract and look for the abstract submission site to open again on 06 March. We look forward to seeing your latest results!

Nivedita Agarwal, M.D.
ISMRM 2023 Program Chair

Submission Guidelines

Rejection of Duplicate Abstracts

Any abstract(s) deemed to duplicate or to contain significant overlap of content will be rejected. Determination of what constitutes duplication, including abstracts submitted in multiple categories or over multiple years, is at the discretion of the AMPC. Details of identified duplicate submissions will be maintained in our database and may jeopardize submission of future abstracts by the same individuals or institutions. The electronic submission system facilitates easy identification of duplicate text and data.

Failure to Present

All accepted works that are not withdrawn before the 28 February 2023 withdrawal deadline must be presented by the author or their designee. A database of late cancellations and no-shows is maintained, and consistent infractions may jeopardize submission of future abstracts by the same individuals or institutions.

Synopsis

Each abstract is accompanied by a 100-word synopsis for inclusion in the online program. It should include a brief summary of the problem, methods, results, and conclusions. The synopsis must include text only, without equations or images, and be without references or citations to items described in the full abstract. We request the use of abstract keywords in the synopsis. This will improve the searchability of your abstract after publication. The synopsis text should NOT be duplicated in the actual abstract

Summary of Main Findings

A 250-character summary of the abstract’s main findings is requested for generation of digital poster previews. It is expected that this content will overlap with the 100-word synopsis. As with the synopsis, summary must include text only, without equations or images, and be without references or citations to items described in the full abstract.

Digital Poster “Teaser” Previews

Presentations will be highlighted using a single figure and information about the authors in an abstract thumbnail. In order to accomplish this, you will be asked for the following:

  1. A choice of a secondary figure (in addition to the primary figure already required)
  2. A “Summary of Main Findings”
  3. An institutional logo image file. If you need to acknowledge more than one institution, you must create a single image containing any necessary logos. Alternatively, you may use a project- or consortium logo instead of institutional logos.

Suggested Abstract Format

We recommend including the following sections, although we also note that there are often good reasons to deviate from this format. In each section, answer the question listed below (do not repeat the actual question in the body of your abstract).

  • INTRODUCTION: “Why was this study/research performed? What unsolved problem are you addressing?”
  • METHODS: “How did you study this problem?”
  • RESULTS: “Report the data, analyses and/or outcomes”
  • DISCUSSION: “How do you interpret the results?”
  • CONCLUSION: “What is the relevance to clinical practice or future research?”
  • REFERENCES: References should use the suggested style below.

Word Limits

The following word limits will apply:

  • Title: 125 characters
  • Synopsis: 100 words
  • Body of the Abstract: 850 words (references not included)
  • Summary of Main Findings: 250 Characters (~35 words)
  • Figures: up to 5 only
  • Figure Captions: 500 characters per caption

References

Cite each source in numerical order using superscript Arabic numerals.

  • Example 1:
    A review of regulations has been complete by the WHO15.
  • Example 2:
    The data were as follows 3,4:
  • Example 3:
    …methods for MR fingerprinting 11-14,25,

At the end of the abstract, list references numerically in the order in which they were cited in the text.

  • Example 1:
    1. Rainier S, Thomas D, Tokarz D, et al. Myofibrillogenesis regulator 1 gene mutations cause paroxysmal dystonic choreoathetosis. Arch Neurol. 2004;61(7):1025‐1029.
  • Example 2:
    2. World Health Organization. Injury: A Leading Cause of the Global Burden of Disease, 2000. Geneva, Switzerland: World Health Organization; 2002.
  • Example 3:
    3. Weiss R. The promise of precision prescriptions. Washington Post. June 24, 2000:A1. http://www.washingtonpost.com. Accessed October 10, 2001.

Further Information

Abstract Content Guidelines

  • Bias: The content may not promote the proprietary interests of any commercial entity. Evident bias in favor of a particular product or company is grounds for rejection. (Reference to the use of a particular company’s products or equipment does not represent bias. Non-data-driven statements of superiority, however, would be considered biased.)
  • Content must be restricted to scientific, engineering, and clinical studies, as well as industry issues and operation of devices. Product/company names should be included only to identify the MR hardware/software/peripherals used but not to promote proprietary interests (see first bullet point).
  • Abstracts must be written in English.
  • All recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for the recommendations as indications or contraindications in the care of patients.
  • All scientific research referred to, reported or used in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
  • Abstracts previously submitted to the ISMRM or to another society/journal, but were not accepted, may be resubmitted.

Abstract Review Criteria

  • Adherence to the Abstract Content Guidelines (as stated above).
  • Duplication of Content (see also above). Multiple submissions of the same or nearly the same abstract is grounds for rejection of all submitted abstracts.
  • Innovation/novelty: advancement of knowledge, and/or improvement of capabilities.
  • Quality: The results should be substantive and not just implied. Where appropriate:
    • Comprehensive statistical analysis should be applied.
    • Images and spectra should be of the highest quality.
  • Impact: The method or data in the abstract should aim to advance or change the field in significant ways. Incremental changes are less likely to be accepted for presentation.

Tip for Authors

  • Contact all co-authors prior to submission. It is considered unethical to submit abstracts listing co-authors who have not agreed to the submission. In general, co-authors will expect to read and approve of the content of an abstract, but at a minimum they should be aware of the submission and consented to being listed as an author.

Publication of Abstracts

The Proceedings will be published electronically only. The full text of all accepted abstracts will be available online two weeks before the meeting to pre-registered attendees only (19 May 2023). If you wish to have access to the Proceedings before the meeting, you must pre-register.

All submitted abstracts are treated as confidential from the time of submission to the publication date of 19 May 2023.

All copyrights to accepted abstracts become the property of ISMRM. No proprietary information may be withheld by authors.

Be sure to read “A Guide to ISMRM’s HTML-Based Late-Breaking Abstract Submission Process” for further details and important formatting requirements!

IMPORTANT!
You MUST create a NEW user account for 2023 late-breaking abstracts on the submission site, even if you submitted a 2023 abstract last fall.

The submission site will not accept any accounts from previous years or from the autumn of 2022.
Please click on the [New to This Site?] link to create a login and password for your 2023 late-breaking submissions.